Market Overview

AVEO Presents Detailed Results of Exploratory Phase 2 Study Evaluating Ficlatuzumab in First-Line Patients with Advanced Non-small Cell Lung Cancer


AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from
an exploratory, randomized Phase 2 study evaluating the combination of
ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib
compared to gefitinib monotherapy in previously untreated Asian subjects
with non-small cell lung cancer (NSCLC) were presented at the 2012
Congress of the European Society for Medical Oncology (ESMO). As
previously reported, the study did not achieve its primary endpoint;
however, the results presented at ESMO suggest that the addition of
ficlatuzumab to gefitinib may be effective in select subsets of patients.

“The insights gleaned from the Phase 2 study, along with new
pharmacodynamic data, show that inhibiting the HGF ligand may be
important in the treatment

See full press release

Posted-In: Earnings News Guidance Asset Sales Management Global


Related Articles (AVEO)

View Comments and Join the Discussion!

UPDATE: Canaccord Genuity Initiates Conn's at Buy on Growth Outlook

WiLAN Acquires Alvarion Patents for $19M